Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2003

01-06-2003

Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma

Authors: Kensei Tobinai, Naokuni Uike, Yoshio Saburi, Takaaki Chou, Tetsuya Etoh, Masato Masuda, Fumio Kawano, Masao Matsuoka, Hirokuni Taguchi, Torahiko Makino, Yoshinobu Asano, Kazuo Tamura, Yasuo Ohashi

Published in: International Journal of Hematology | Issue 5/2003

Login to get access
Metadata
Title
Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma
Authors
Kensei Tobinai
Naokuni Uike
Yoshio Saburi
Takaaki Chou
Tetsuya Etoh
Masato Masuda
Fumio Kawano
Masao Matsuoka
Hirokuni Taguchi
Torahiko Makino
Yoshinobu Asano
Kazuo Tamura
Yasuo Ohashi
Publication date
01-06-2003
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2003
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02986621

Other articles of this Issue 5/2003

International Journal of Hematology 5/2003 Go to the issue

Case Report

T-Cell Acute Lymphoblastic Leukemia as a Secondary Leukemia after a 3-Year Remission of Acute Myelocytic Leukemia

OriginalPaper

Two Cases of Acute Myeloblastic Leukemia Evolving from Aplastic Anemia

Progress in Hematology

Immunotherapy for Lymphomas

Case Report

Epstein-Barr Virus-Associated Anaplastic Large Cell Variant of Diffuse Large B-Cell-Type Non-Hodgkin’s Lymphoma with Concurrent P53 Protein Expression

OriginalPaper

Clonal Analysis of Granulocyte-Monocyte Colony-Forming Unit Cells with the Human Androgen Receptor Gene in Chronic Myeloid Leukemia

OriginalPaper

Generation of a Chimeric Mouse Reconstituted with Green Fluorescent Protein-Positive Bone Marrow Cells: A Useful Model for Studying the Behavior of Bone Marrow Cells in Regeneration In Vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits